brentuximab vedotin
takeda,seagen
['brentuximab vedotin', 'improve', 'hodgkin', 'lymphoma']
#asco22: dr. andrew evens ( ) &amp; colleagues present first-line brentuximab vedotin plus chemotherapy to improve overall survival in patients w/ stage iii/iv classical hodgkin #lymphoma..." 
Rutgers Cancer Institute of New Jersey is the state’s only NCI-designated Comprehensive Cancer Center and a leader in patient care and cancer research.